CVS Health Corp
Q1 2026 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.73%.
Did CVS Beat Earnings? Q1 2026 Results
CVS Health delivered a strong first quarter of 2026, beating Wall Street expectations on both the top and bottom lines to extend its consensus EPS beat streak to four consecutive quarters. The healthcare giant posted adjusted EPS of $2.57, clearing the $2.21 consensus estimate by 16.47%, while revenue climbed 6.2% year over year to $100.43 billion, beating expectations of $95.02 billion by 5.69%. The standout driver was a dramatic turnaround in the Health Care Benefits segment, where adjusted operating income surged 52.6% to $3.04 billion as the medical benefit ratio improved to 84.6% from 87.3%, largely because the prior year had been weighed down by a $448 million premium deficiency reserve tied to the individual exchange business CVS has since exited. Analyst commentary in recent weeks had flagged improving Medicare Advantage utilization trends as a sector-wide tailwind, and CVS appeared to benefit from that dynamic. Management raised full-year 2026 adjusted EPS guidance to $7.30-$7.50 and lifted cash flow from operations guidance to at least $9.50 billion, while cautioning that elevated cost trends and potential macro headwinds warrant a measured outlook for the remainder of the year.
- Health Care Benefits margin recovery plan execution driving 52.6% adjusted operating income growth
- Improved underlying performance in Government business
- Absence of $448 million premium deficiency reserve recorded in prior year individual exchange product line
- Pharmacy drug mix and brand inflation driving Health Services revenue growth
- Rite Aid prescription file acquisitions contributing to increased prescription volume
- Prior years' health care costs payable estimates developed favorably by $1.1 billion
“CVS Health continues to provide what people want most from health care: a connected, convenient, cost-effective engagement experience across our unique collection of businesses. We build trust every day in communities across the country by providing better access, affordability and care to nearly 185 million people. Our positive performance is driven by strong execution across our enterprise. We will continue to build momentum through delivering on our strategy and a steadfast focus on our purpose - to simplify health care one person, one family and one community at a time.”
CVS Health CEO, on the earnings call
Forward Guidance & Outlook
CVS Health raised its full-year 2026 guidance: GAAP diluted EPS range increased to $6.24-$6.44 from $5.94-$6.14; Adjusted EPS range increased to $7.30-$7.50 from $7.00-$7.20; cash flow from operations guidance increased to at least $9.5 billion from at least $9.0 billion; and total revenues projected at least $405.0 billion. The guidance raise reflects increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.
CVS YoY Financials
CVS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.